InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

- Current share price for SPL : $0.815

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$389 DEP Docetaxel Trial Dose Exceeds Common Taxotere Dose Level 30 Apr 2015 9:34AM $0.510 $0.815 risen by 59.80%
$389 Securities Dealing Policy 22 Apr 2015 4:28PM $0.525 $0.815 risen by 55.24%
$389 Interim Report and Half-Year Financial Results 16 Feb 2015 10:07AM $0.540 $0.815 risen by 50.93%
$389 Appendix 4C - Quarterly Cashflow Report 28 Jan 2015 10:00AM n/a $0.815 n/a
$389 Japan VivaGel condom classification impacts launch timing 5 Dec 2014 9:15AM $0.520 $0.815 risen by 56.73%
$389 Marketing Clearance for VivaGel condom in New Zealand 28 Nov 2014 11:15AM $0.495 $0.815 risen by 64.65%
$389 Response to ASX Price Query 17 Nov 2014 3:05PM $0.525 $0.815 risen by 55.24%
$389 Starpharmas Priostar Glyphosate Patent Allowed in China 13 Nov 2014 9:23AM $0.585 $0.815 risen by 39.32%
$389 Appendix 4C - quarterly 31 Oct 2014 2:02PM $0.560 $0.815 risen by 45.54%
$389 Starpharma receives $4.2M R&D tax incentive refund 29 Oct 2014 10:36AM $0.650 $0.815 risen by 25.38%
$389 DEP docetaxel - longer duration and increased exposure 20 Oct 2014 10:58AM $0.660 $0.815 risen by 23.48%
$389 VivaGel condom approved for sale with launch imminent 2 Oct 2014 10:44AM $0.715 $0.815 risen by 13.99%
$389 SPP Record Date Clarification 22 Sep 2014 3:16PM $0.665 $0.815 risen by 22.56%
$389 Starpharma completes A$18 million placement, SPP to follow 22 Sep 2014 9:29AM $0.690 $0.815 risen by 18.12%
$389 Trading Halt 18 Sep 2014 9:29AM $0.710 $0.815 risen by 14.79%
$389 Annual report and full year financial results 13 Aug 2014 4:38PM $0.730 $0.815 risen by 11.64%
$389 Appendix 4C - Quarterly Cashflow Report 31 Jul 2014 9:18AM $0.755 $0.815 risen by 7.95%
$389 VivaGel condom receives TGA device certification 21 Jul 2014 10:38AM $0.700 $0.815 risen by 16.43%
$389 FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial 14 Jul 2014 10:10AM $0.575 $0.815 risen by 41.74%
$389 Starpharma clinical trial programs accelerating 5 Jun 2014 10:46AM $0.595 $0.815 risen by 36.97%
$389 Appendix 4C - Quarterly Cashflow Report 30 Apr 2014 2:31PM $0.710 $0.815 risen by 14.79%
$389 Starpharma expands Drug Delivery Program with AstraZeneca 7 Apr 2014 8:27AM $0.750 $0.815 risen by 8.67%
$389 VivaGel-coated condom approved for marketing in Japan 14 Mar 2014 9:17AM $0.770 $0.815 risen by 5.84%
$389 Starpharma Interim Report and Half-year Financial Results 24 Feb 2014 1:20PM $0.685 $0.815 risen by 18.98%
$389 Appendix 4C - Quarterly Cashflow Report 30 Jan 2014 1:48PM $0.785 $0.815 risen by 3.82%

676 - 700 of 888 results

Page 28 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.